share_log

T2 Biosystems | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nathan D. Hukill(69.5%),CR Group L.P.(69.5%), etc.

T2 Biosystems | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nathan D. Hukill(69.5%),CR Group L.P.(69.5%), etc.

T2 Biosystems | SC 13D/A：超过5%持股股东披露文件(修正)-Nathan D. Hukill(69.5%),CR Group L.P.(69.5%)等
美股sec公告 ·  05/13 19:24
Moomoo AI 已提取核心信息
On May 9, 2024, T2 Biosystems, Inc., a medical diagnostic company, experienced a significant change in its ownership structure as detailed in an amended Schedule 13D filing with the U.S. Securities and Exchange Commission. The filing indicates that a group led by Nathan D. Hukill, including entities such as CR Group L.P. and various CRG Partners funds, has acquired a substantial portion of the company's common stock. The shares were obtained in exchange for the cancellation of outstanding loans previously extended to T2 Biosystems under a Term Loan Agreement dating back to December 30, 2016. As a result of these transactions, the group collectively holds approximately 69.5% of the issued and outstanding shares of T2 Biosystems' common stock. This percentage includes shares acquired through the conversion...Show More
On May 9, 2024, T2 Biosystems, Inc., a medical diagnostic company, experienced a significant change in its ownership structure as detailed in an amended Schedule 13D filing with the U.S. Securities and Exchange Commission. The filing indicates that a group led by Nathan D. Hukill, including entities such as CR Group L.P. and various CRG Partners funds, has acquired a substantial portion of the company's common stock. The shares were obtained in exchange for the cancellation of outstanding loans previously extended to T2 Biosystems under a Term Loan Agreement dating back to December 30, 2016. As a result of these transactions, the group collectively holds approximately 69.5% of the issued and outstanding shares of T2 Biosystems' common stock. This percentage includes shares acquired through the conversion of Series A and Series B Convertible Preferred Stock on May 9, 2024. The filing also notes that no other transactions in the common stock have been made by the reporting persons in the last 60 days, and no other person is known to have the right to receive dividends or proceeds from the sale of the shares owned by the reporting group.
2024年5月9日，医疗诊断公司T2 Biosystems, Inc. 的所有权结构发生了重大变化，详情见向美国证券交易委员会提交的经修订的附表13D。文件显示，由内森·哈基尔领导的集团，包括CR集团有限责任公司和各种CRG Partners基金等实体，已经收购了该公司很大一部分普通股。获得这些股份是为了换取取消先前根据可追溯到2016年12月30日的定期贷款协议向T2 Biosystems提供给T2 Biosystems的未偿贷款。由于这些交易，该集团共持有T2 Biosystems普通股已发行和流通股的约69.5％。该百分比包括2024年5月9日通过转换A系列和B系列可转换优先股获得的股份。该文件还指出，在过去的60天中，申报人没有进行任何其他普通股交易，据知没有其他人有权获得分红或出售申报集团拥有的股票的收益。
2024年5月9日，医疗诊断公司T2 Biosystems, Inc. 的所有权结构发生了重大变化，详情见向美国证券交易委员会提交的经修订的附表13D。文件显示，由内森·哈基尔领导的集团，包括CR集团有限责任公司和各种CRG Partners基金等实体，已经收购了该公司很大一部分普通股。获得这些股份是为了换取取消先前根据可追溯到2016年12月30日的定期贷款协议向T2 Biosystems提供给T2 Biosystems的未偿贷款。由于这些交易，该集团共持有T2 Biosystems普通股已发行和流通股的约69.5％。该百分比包括2024年5月9日通过转换A系列和B系列可转换优先股获得的股份。该文件还指出，在过去的60天中，申报人没有进行任何其他普通股交易，据知没有其他人有权获得分红或出售申报集团拥有的股票的收益。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息